Nateglinide clinical trials
How each study uses Nateglinide is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- 22 Dec 2000 · STARLIX · NDA 021204 (FDA, Drugs@FDA)
- European Union
- 3 Apr 2001 · Starlix · EMEA/H/C/000335 (EMA; now withdrawn)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
12 studies that test it; most in 2009 (3)
| Year | Studies |
|---|---|
| 2002 | 1 |
| 2003 | 2 |
| 2004 | 1 |
| 2006 | 1 |
| 2007 | 2 |
| 2009 | 3 |
| 2011 | 1 |
| 2012 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 9 · Other 4
Novartis Pharmaceuticals (4) · Astellas Pharma Inc (2) · Dr. Reddy's Laboratories Limited (2) · Atheline Major-Pedersen (1) · Ajou University School of Medicine (1) · IlDong Pharmaceutical Co Ltd (1) · Inje University (1) · University of Oslo School of Pharmacy (1)
Often tested with
Tested in the same studies.
Ipragliflozin (1) · Glimepiride (1) · Metformin (1) · Acarbose (1)
Related medicines
As reviewed, each with the page that says it.
- One of Hypoglycemic Agents source
Studies
Open first, then newest update. How each study uses Nateglinide is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 13
- A Study to Assess Safety and Efficacy of ASP1941 in Combination With Nateglinide in Type 2 Diabetic PatientsCompletedPhase 3Astellas Pharma IncNCT01316107Written as nateglinideHow we know
- Insulin Resistance and Vessel Function After Meals: Does Early Intervention Make a Difference?CompletedPhase 4Atheline Major-PedersenNCT00259168Written as NateglinideHow we know
- Study of the Durability of Glycemic Control With NateglinideCompletedPhase 4Ajou University School of MedicineNCT00858013Written as NateglinideHow we know
- Safety and Efficacy of Nateglinide in Patients With Type 2 Diabetes Already Taking Insulin Glargine, Metformin and/or Pioglitazone or RosiglitazoneCompletedPhase 4Novartis PharmaceuticalsNCT00402909Written as NateglinideHow we know
- A Open-label, Single-dose, 2-Sequence, 2-Period, Crossover Study to Assess Safety and Pharmacokinetics of a Nateglinide/Metformin HCl Combined Tablet Compared With a Nateglinide 120 mg Tablet and Metformin HCl 500 mg Tablet Under Fasting Conditions in Healthy Male SubjectsCompletedPhase 1IlDong Pharmaceutical Co LtdNCT02088918Written as NateglinideHow we know
- Effects of Nateglinide on Postprandial Glucose Excursion by Restoring Early Phase Insulin SecretionCompletedPhase 4Novartis PharmaceuticalsNCT01030952Written as NateglinideHow we know
- Effects of Nateglinide vs Acarbose on Postprandial Glucose Fluctuation, Dyslipidemia, and Inflammatory FactorsCompletedPhase 4Novartis PharmaceuticalsNCT00928889Written as Nateglinide 120 mgHow we know
- A Pilot Study to Evaluate the Effects of Nateglinide vs. Glibenclamide on Renal Hemodynamics and Albumin ExcretionCompletedPhase 4Novartis PharmaceuticalsNCT00238472Written as nateglinideHow we know
- Bioequivalence Study of Nateglinide Tablets 120 mg of Dr. Reddy's Laboratories Limited Under Fed ConditionCompletedPhase 1Dr. Reddy's Laboratories LimitedNCT01160029Written as NateglinideHow we know
- Bioequivalence Study of Nateglinide Tablets 120 mg of Dr. Reddy's Laboratories Limited Under Fasting ConditionCompletedPhase 1Dr. Reddy's Laboratories LimitedNCT01159158Written as NateglinideHow we know
- The Effects of Nateglinide and Acarbose on the Post-Prandial Glucose Control in Type 2 Diabetic PatientsCompletedPhase 4Inje UniversityNCT00437918Written as nateglinideHow we know
- Nateglinide: a Double Blind Add-on Study With Pioglitazone for Type 2 Diabetic PatientsCompletedPhase 2/3Astellas Pharma IncNCT00189774Written as nateglinideHow we know
- Efficacy and Safety of Nateglinide Treatment in Renal Transplant RecipientsCompletedPhase 4University of Oslo School of PharmacyNCT00319189Written as NateglinideHow we know
Codes
What other systems call Nateglinide · ClinicalTrials.gg INT006788
- MeSH (NLM) D000077715NateglinideConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 41X3PWK4O2NATEGLINIDEConfirmed FDA, NLM, Wikidata
- RxNorm 274332Confirmed FDA, Wikidata
- Wikidata Q2254797nateglinideConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C61858NateglinideOne source FDA
- DrugBank DB00731One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000077715 | Nateglinide | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 41X3PWK4O2 | NATEGLINIDE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 274332 | — | Confirmed FDA, Wikidata |
| Wikidata | Q2254797 | nateglinide | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C61858 | Nateglinide | One source FDA |
| DrugBank | DB00731 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.